Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 3/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 3/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw813893 SCHEMBL675587 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL6219768 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL16439470 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL675586 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL675588 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL23752149 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| SCHEMBL4704233 | 0.89 | F10 (0.80) | F10F2KLKB1PLAT | |
| SCHEMBL4704238 | 0.89 | F10 (0.80) | F10F2KLKB1PLAT | |
| SCHEMBL6666834 | 0.86 | F10 (1.00) | F10F2KLKB1PLAT | |
| SCHEMBL4488532 | 0.86 | F10 (1.00) | F10F2KLKB1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567519-B1 | CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | claimed |
| US-7517879-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-14 | — | — | US | disclosed |
| EP-1567519-B1 | CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| EP-1567519-A2 | CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004052878-A2 | CRYSTALLINE DERIVATIVE OF 2- (5-CHLOROTHIEN-2-YL)-N- ((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL) ETHENSULFONAMIDE | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | F10 10/4885F2 2/4885KLKB1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.